Introduction

Angiotensin-receptor blockers haw hold convenient anti-arrhythmic personalty in atrial arrhythmia (AF), but their mechanisms are not full understood. In this study, we proven the hypotheses that (i) candesartan reduces atrial fibrillatory evaluate and (ii) fibrillatory evaluate and its salutation to candesartan are attendant with the outcome of cardioversion. For this purpose, a post hoc subanalysis of the randomized, placebo-controlled CAPRAF (Candesartan in the Prevention of Relapsing Atrial Fibrillation) effort was performed.

Methods and results

Patients with AF undergoing electrical cardioversion were irregular to obtain candesartan 8 mg erst regular (n = 58) or matched placebo (n = 66) and no added collection I or threesome anti-arrhythmic drugs. Fibrillatory evaluate was observed from ECG advance V1 at line and at the period of cardioversion using comprehensive QRST cancellation and time–frequency analysis. The norm instance on communication was 29 days. Candesartan baritone fibrillatory evaluate [399 ± 48 vs. 388 ± 49 fibrillations/min (fpm), P = 0.04], but not placebo (402 ± 58 vs. 402 ± 61 fpm, P = 0.986). Candesartan personalty were exclusive observed if the line fibrillatory evaluate was broad [>420 fpm: 445 ± 21 vs. 415 ± 49 fpm, P = 0.006 vs. grey (360–420 fpm): 397 ± 19 vs. 391 ± 37 fpm, P = 0.351 vs. baritone (<360 fpm): 326 ± 26 vs. 338 ± 29 fpm, P = 0.179]. Cardioversion success was 100% in patients with an on-treatment evaluate <360 fpm vs. 83% in patients with higher rates (P = 0.02). Risk for AF repetition was kindred in patients with baritone (64%), grey (75%), or broad on-treatment rates (63%, P = 0.446) and was also autarkical of candesartan personalty on the fibrillatory rate.

Conclusion

In patients with continual AF, candesartan decreases the fibrillatory rate, but this gist is limited to patients with broad line fibrillatory rates and is not related with reinforced cardioversion outcome. Fibrillatory rates <360 fpm are related with flourishing cardioversion, but not with AF recurrence.

Tags: ATM, Drugs, ESA, Led, Risk